Healthcare resource utilization patterns among patients with Parkinson’s disease psychosis and dementia: analysis of US Medicare beneficiaries treated with pimavanserin versus other-atypical antipsychotics or versus quetiapine
Patients initiating PIM-monotherapy for PDP+D experienced 12% lower all-cause inpatient hospitalizations vs. Other-AAPs or QUE. These results are consistent with prior real-world research in PDP with or without dementia.
Authors
- Krithika Rajagopalan (ORCID: https://orcid.org/0000-0002-4878-0822)
- Nazia Rashid (ORCID: https://orcid.org/0000-0002-4227-1234)
- Lambros Chrones (ORCID: https://orcid.org/0000-0001-7822-9364)
- Dilesh Doshi (ORCID: https://orcid.org/0009-0006-0970-2158)
- Daksha Gopal (ORCID: https://orcid.org/0000-0003-2710-980X)
Institutions
- Acadia Pharmaceuticals (United States) (US)
- Health Outcomes Solutions (United States) (US)
- Health Economics and Outcomes Research (United Kingdom) (GB)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-04-02
- DOI
- https://doi.org/10.1080/13696998.2025.2487358
- Citations
- 2
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.78